That is only ~ 160 M market cap. Waaaay too low. Try 180.00 PPS (3 B marketcap) for starters and potential to go much higher with Seliciclib and CYC065 in RA and other inflammatory diseases. Don't let the current PPS shape your expectations for these drugs. Stay focused on the markets these drugs will serve. Gemzar did 1.6 Billion and SAP outperforms Gemzar on every metric AND has the huge potential of treating solid Tumors (Gemzar only active in Hematological applications). Only 1 Billion in sales will get us to 180.00.